SUMMARY It has been suggested that mercaptans are important factors in the pathogenesis of hepatic encephalopathy. Using a gas liquid chromatographic technique which uses propanethiol as internal standard and a sulphur specific detector, blood methanethiol concentration was found to be significantly risen in encephalopathic patients with liver disease (13.2±1.0 nmol/ml; n=47) compared with control subjects (5-7±0-3, n=29; p<0-05) and non-encephalopathic patients with liver disease (7.7±1.1, n=35; p<005) but ethanethiol and dimethylsulphide concentrations were similar in the three groups. Blood methanethiol, however, was not clearly related to coma grade, similar values being found in deeply comatosed patients to those showing only mild cerebral dysfunction. When rats were injected with 40-120 ,umol methanethiol a range of responses was obtained which varied between normal consciousness and coma. The minimum blood concentration of methanethiol associated with coma (200 nmol/ml) was at least 10-fold greater than in patients with hepatic encephalopathy but brain concentrations were similar in comatose rats and those which remained awake. Blood methanethiol concentrations were similar in control and germ free rats and did not rise in cirrhotics or controls after ingestion of 2 g methionine. It is concluded that while methanethiol may accumulate in hepatic coma, it is unlikely to be of major pathogenetic importance. Endogenous mercaptans are unlikely to originate from bacterial metabolism in the gut.
The precise pathogenesis of hepatic encephalopathy is poorly understood although a number of substances have been implicated because they cause coma in experimental animals. These include ammonia, short chain fatty acids and mercaptans and synergism between these substances has been shown.' Other possible mechanisms include an accumulation of false neurotransmitters such as octopamine and a fall in normal neurotransmitters such as dopamine and noradrenaline.2 Recent studies in animals, however, have shown a marked fall in cerebral neurotransmitters after intraventricular injection of octopamine while no apparent change in consciousness was observed.3 Furthermore noradrenaline concentrations were similar in the brains of patients with hepatic encephalopathy compared with controls while dopamine concentrations were normal or increased.4 Brain octopamine concentrations were not significantly greater than in controls. 4 Mercaptans were first implicated in hepatic coma when methanethiol was isolated from the urine. and control rats, no significant differences being observed ( Blood methanethiol concentrations in rats remaining awake were considerably greater than in patients with hepatic coma (Fig. 4) . Rats just unable to stand and those in coma showed even higher concentrations so that the threshold for coma appeared to be associated with a blood concentration about 10-fold greater than in patients with hepatic coma. There was considerable overlap in the brain concentrations of methanethiol, some rats in coma having concentrations similar to those seen in rats which were awake (Fig. 4) .
Dimethylsulphide concentrations in blood in rats Figure 6 . There was no between ammonia concentrations and m (r=0-164). In nine patients sequential observat different grades of coma showed that m concentrations were always higher in severe grade of coma (Fig. 7) . These however, were small and were of n predicting the coma grade. Methane thiol (Oumol/t) Fig. 6 Relationship between ammonia and methanethiol concentrations in patients with hepatic encephalopathy. Correlation was not significant (r=0-164). The coma was graded as described by Trey and Davidson.11 concentration was found in a non-comatose outpatient with primary biliary cirrhosis. The mean concentration of methanethiol in encephalopathic patients, however, was significantly increased compared to non-encephalopathic patients and controls but ethanethiol and dimethylsulphide concentrations were similar in all groups. Blood ethanethiol concentrations were similar to those previously associated with coma in the rat (0.2 ,umol/l)l while blood dimethylsulphide concentrations were very much lower than those associated with coma in the rat (7 mmol/l). Phear et al14 showed neuropsychiatric changes in cirrhotics fed methionine, an effect which occurred without change in blood ammonia concentrations and which could be prevented by the administration of chlortetracycline. Patients developing encephalopathy received a mean of 27 g methionine over two and a half days. It was suggested that this effect of methionine was due to a toxic breakdown product other than ammonia. In the present study blood methanethiol, ethanethiol, and dimethylsulphide did not change significantly after ingestion of 2 g of methionine and decreased concentrations were not observed in germ free rats. It thus seems unlikely that bacterial metabolism in the gut is the major source of engdogenous mercaptans in man. Whether methanethiol was the toxic metabolite of methionine postulated by Phear14 cannot be determined from the present study because of the large difference in methionine dose administered.
Brain concentrations in rats in coma were significantly greater than in control rats but there was considerable overlap between rats treated with methanethiol which remained awake and those which went into coma. This suggests coma after methanethiol is not induced by this substance alone but that other factors are necessary. Whether methanethiol blocks neurotransmission or induces a metabolic modification in the brain is unknown.
Dimethylsulphide concentrations rose sharply after methanethiol administration suggesting endogenous conversion to dimethylsulphide in the circulation. This could account for the rise in dimethylsulphide concentrations in breath which has been reported in patients with cirrhosis.7
The present studies do not suggest that mercaptans play an important role in the pathogenesis of hepatic encephalopathy. Concentrations of methanethiol are certainly increased in the blood of many patients with hepatic coma but this appears to be the result of the severe derangement of metabolic function which occurs in patients with liver disease.
